InflaRx N.V. Common Stock
Symbol: IFRX (NASDAQ)
1.70
▲ (45.30%) 0.530
Company Description:
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Key Stats
- Today's Open: $1.38
- Today's High: $1.745
- Today's Low: $1.231
- Today's Volume: 4.25M
- Yesterday Close: $1.17
- Yesterday High: $1.29
- Yesterday Low: $0.9751
- Yesterday Volume: 1.89M
- Last Min Volume: 1.31K
- Last Min High: $1.701
- Last Min Low: $1.7
- Last Min VWAP: $1.70054
Company Profile
- Name: InflaRx N.V. Common Stock
- Website: https://www.inflarx.de
- Listed Date: 2017-11-08
- Location: ,
- Market Status: Active
- CIK Number: 0001708688
- SIC Code:
- SIC description:
- Market Cap: $79.26M
- Round Lot: 100
- Outstanding Shares: 67.75M
- Asset Type: CS
RECENT FILINGS FOR IFRX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-07 | 6-K | View |
| 2025-07-14 | 6-K | View |
| 2025-06-27 | 6-K | View |
| 2025-06-11 | UPLOAD | View |
| 2025-06-03 | CORRESP | View |
| 2025-05-28 | 6-K | View |
| 2025-05-22 | UPLOAD | View |
| 2025-05-07 | 6-K | View |
| 2025-04-24 | 6-K | View |
| 2025-04-03 | 6-K | View |
| 2025-03-20 | 20-F | View |
| 2025-03-20 | 6-K | View |
| 2025-02-18 | 6-K | View |
| 2025-02-18 | 424B5 | View |
| 2025-02-13 | 424B5 | View |
| 2025-01-15 | 6-K | View |
| 2024-12-20 | 6-K | View |
| 2024-11-15 | 6-K | View |
| 2024-11-08 | 6-K | View |
| 2024-08-08 | 6-K | View |
Latest News on IFRX